These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22672147)

  • 21. Inhibitor development in patients with hemophilia: an overview.
    Leissinger CA
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
    [No Abstract]   [Full Text] [Related]  

  • 22. High titre inhibitor to factor VIII in a haemophilia carrier.
    Marino R; Malcangi G; Margaglione M; Ettorre CP
    Haemophilia; 2014 May; 20(3):e237-40. PubMed ID: 24731130
    [No Abstract]   [Full Text] [Related]  

  • 23. Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
    Groomes CL; Gianferante DM; Crouch GD; Parekh DS; Scott DW; Lieuw K
    Pediatr Blood Cancer; 2016 May; 63(5):922-4. PubMed ID: 26739399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
    Hu G; Guo D; Key NS; Conti-Fine BM
    Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of factor VIII inhibitors.
    Acharya SS; DiMichele DM
    Best Pract Res Clin Haematol; 2006; 19(1):51-66. PubMed ID: 16377541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of factor VIII inhibitors in two patients with moderate haemophilia A.
    Paschal RD; Meeks SL; Neff AT
    Haemophilia; 2013 Jan; 19(1):e55-7. PubMed ID: 23171275
    [No Abstract]   [Full Text] [Related]  

  • 27. Controversies regarding the prophylactic management of adults with severe haemophilia A.
    Valentino LA
    Haemophilia; 2009 Dec; 15 Suppl 2():5-18, quiz 19-22. PubMed ID: 20041959
    [No Abstract]   [Full Text] [Related]  

  • 28. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.
    Franchini M; Girelli D; Olivieri O; Castaman G; Lippi G; Poli G; Salvagno GL; Tagariello G; Giuffrida A; de Gironcoli M; Morfini M; Berntorp E; Gandini G
    Haemophilia; 2006 Jul; 12(4):448-51. PubMed ID: 16834751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
    Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
    Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
    [No Abstract]   [Full Text] [Related]  

  • 30. The importance of inhibitor eradication in clinically complicated hemophilia A patients.
    Oldenburg J; Young G; Santagostino E; Escuriola Ettingshausen C
    Expert Rev Hematol; 2018 Nov; 11(11):857-862. PubMed ID: 30286680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 34. The correlation between gene mutations and inhibitor development in patients with haemophilia A in southern Iran.
    Haghpanah S; Sahraiian M; Afrasiabi A; Enayati S; Peyvandi F; Karimi M
    Haemophilia; 2011 Sep; 17(5):820-1. PubMed ID: 21371201
    [No Abstract]   [Full Text] [Related]  

  • 35. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
    Leissinger CA
    Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitor to factor VIII in mild haemophilia.
    Kesteven PJ; Holland LJ; Lawrie AS; Savidge GF
    Thromb Haemost; 1984 Aug; 52(1):50-2. PubMed ID: 6437010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acquired haemophilia in a patient treated with interferon-α for hepatitis C infection.
    Goyal J; Tyagi P; Kumar N
    Haemophilia; 2012 May; 18(3):e73-4. PubMed ID: 22404644
    [No Abstract]   [Full Text] [Related]  

  • 38. Evaluation of factor VIII pharmacokinetics and anti-factor VIII antibodies in four boys with haemophilia A and a poor clinical response to factor VIII.
    Kempton CL; Meeks SL; Donald Harvey R; Abshire TC
    Haemophilia; 2011 Jan; 17(1):155-6. PubMed ID: 20579112
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and efficacy of recombinant activated factor VII for long-term secondary prophylaxis in a haemophilia boy with high-titre inhibitors.
    Chuansumrit A; Sirachainan N; Panuwannakorn M; Wongwerawattanakoon P; Kadegasem P; Choeyprasert W; Sasanakul W
    Haemophilia; 2013 May; 19(3):e182-3. PubMed ID: 23600908
    [No Abstract]   [Full Text] [Related]  

  • 40. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.